Abstract
Depsipeptide, FR901228, has demonstrated potent in vitro and in vivo cytotoxic activity against murine and human tumor cell lines. In the laboratory, it has been shown to be a histone deacetylase (HDAC) inhibitor. In a phase I trial of depsipeptide conducted at the National Cancer Institute, 3 patients with cutaneous T-cell lymphoma had a partial response, and 1 patient with peripheral T-cell lymphoma, unspecified, had a complete response. Sézary cells isolated from patients after treatment had increased histone acetylation. These results suggest that inhibition of HDAC is a novel and potentially effective therapy for patients with T-cell lymphoma.
Publication types
-
Case Reports
-
Clinical Trial
-
Clinical Trial, Phase I
MeSH terms
-
Acetylation / drug effects
-
Aged
-
Anti-Bacterial Agents / administration & dosage*
-
Anti-Bacterial Agents / pharmacology
-
Antibiotics, Antineoplastic / administration & dosage*
-
Antibiotics, Antineoplastic / pharmacology
-
Depsipeptides*
-
Enzyme Inhibitors / pharmacology
-
Histone Deacetylase Inhibitors
-
Histones / blood
-
Histones / metabolism
-
Humans
-
Lymphoma, T-Cell, Cutaneous / blood
-
Lymphoma, T-Cell, Cutaneous / drug therapy*
-
Lymphoma, T-Cell, Cutaneous / pathology
-
Lymphoma, T-Cell, Peripheral / blood
-
Lymphoma, T-Cell, Peripheral / drug therapy*
-
Lymphoma, T-Cell, Peripheral / pathology
-
Male
-
Middle Aged
-
Peptides, Cyclic*
-
Remission Induction
-
Skin Neoplasms / blood
-
Skin Neoplasms / drug therapy*
-
Skin Neoplasms / pathology
-
Treatment Outcome
Substances
-
Anti-Bacterial Agents
-
Antibiotics, Antineoplastic
-
Depsipeptides
-
Enzyme Inhibitors
-
Histone Deacetylase Inhibitors
-
Histones
-
Peptides, Cyclic
-
romidepsin